Malin Lindstedt
YOU?
Author Swipe
View article: ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade Open
Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. …
View article: Considerations and Software for Successful Immune Cell Deconvolution Using Proteomics Data
Considerations and Software for Successful Immune Cell Deconvolution Using Proteomics Data Open
Inferring the cell-type composition of bulk samples can provide biological insight. While bulk transcriptomics data has been extensively used for this purpose, the use of proteomics data has remained unexplored until recently. This study e…
View article: Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases
Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases Open
[This corrects the article DOI: 10.3389/fimmu.2024.1439413.].
View article: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases
The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases Open
Tertiary Lymphoid Structures (TLS) are organized aggregates of immune cells such as T cells, B cells, and Dendritic Cells (DCs), as well as fibroblasts, formed postnatally in response to signals from cytokines and chemokines. Central to th…
View article: In vivo dendritic cell reprogramming for cancer immunotherapy
In vivo dendritic cell reprogramming for cancer immunotherapy Open
Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an…
View article: A cancer immunotherapy modality based on dendritic cell reprogramming<i>in vivo</i>
A cancer immunotherapy modality based on dendritic cell reprogramming<i>in vivo</i> Open
Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach…
View article: Next-generation CD40 agonists for cancer immunotherapy
Next-generation CD40 agonists for cancer immunotherapy Open
There are multiple promising next-generation approaches beyond monospecific antibodies targeting CD40 in immuno-oncology. Enhancing efficacy is the most important driver for this development, and approaches that maximize the ability of CD4…
View article: IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept
IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept Open
Drug-induced hepatotoxicity constitutes a major reason for non-approval and post-marketing withdrawal of pharmaceuticals. In many cases, preclinical models lack predictive capacity for hepatic damage in humans. A vital concern is the integ…
View article: Fine tuning of the innate and adaptive immune responses by Interleukin-2
Fine tuning of the innate and adaptive immune responses by Interleukin-2 Open
Novel immunotherapies for cancer and other diseases aim to trigger the immune system to produce durable responses, while overcoming the immunosuppression that may contribute to disease severity, and in parallel considering immunosafety asp…
View article: Human papillomavirus-associated head and neck squamous cell carcinoma cells rely on glycolysis and display reduced oxidative phosphorylation
Human papillomavirus-associated head and neck squamous cell carcinoma cells rely on glycolysis and display reduced oxidative phosphorylation Open
Introduction Head and neck squamous cell carcinoma (HNSCC) constitutes a heterogeneous group of cancers. Human papilloma virus (HPV) is associated with a subtype of HNSCC with a better response to treatment and more favorable prognosis. Mi…
View article: Targeted spatial proteomic analysis of CD8+ T- and myeloid cells in tonsillar cancer
Targeted spatial proteomic analysis of CD8+ T- and myeloid cells in tonsillar cancer Open
Background Tonsillar cancer is caused by high-risk human papillomavirus (HPV), tobacco smoking, and alcohol abuse. Aspects of the patient’s immune response to this disease have arisen as prognostic factors and treatment targets, reflecting…
View article: 837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro Open
Background ATOR-4066 is a preclinical stage bispecific antibody targeting CD40 and CEACAM5, developed from Alligator's novel Neo-X-Prime™ antibody technology platform, which is able to induce a neoantigen specific T-cell response by activa…
View article: Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody Open
CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a…
View article: Restoring tumor immunogenicity with dendritic cell reprogramming
Restoring tumor immunogenicity with dendritic cell reprogramming Open
Decreased antigen presentation contributes to the ability of cancer cells to evade the immune system. We used the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1) to reprogram cancer cells into professional ant…
View article: Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer
Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer Open
Nasopharyngeal cancer (NPC) is a malignant tumor. In a recent publication, we described the presence and distribution of CD8+ T cells in NPC and used the information to identify ‘inflamed’, ‘immune-excluded’, and ‘desert’ immune phenotypes…
View article: Data from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Data from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Purpose: Local administration of immune-activating antibodies may increase the efficacy and reduce the immune-related adverse events associated with systemic immunotherapy of cancer. Here, we report the development and affinity maturation …
View article: Supplementary Methods from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Methods from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Methods
View article: Supplementary Figure 1 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 1 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 1. A) Annexin V positive moDC after ADC-1013 stimulation and B) the effect of cross-linking on percentage of Annexin stained cells (n=6).
View article: Supplementary Methods from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Methods from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Methods
View article: Supplementary Figure 5 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 5 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 5. hCD40tg mice with one tumor on each flank were treated peritumorally in the tumor on the right flank. Tumor volumes of individual untreated tumors (red) and treated tumors (black) are displayed.
View article: Supplementary Figure 4 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 4 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 4. Anti-tumor effect on MB49 tumors. ADC-1013 generates a significant anti-tumor effect on CD40 negative MB49 cells in hCD40tg mice. Treatment with ADC-1013 or isotype control was performed on day 7 and 10 post tumor i…
View article: Supplementary Tables from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Tables from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Table 1. Selection strategy Supplementary Table 2. Kinetic parameters for ADC-1013 and B44 measured by Biacore Supplementary Table 3. In vitro potency (EC50) of ADC-1013 in DC and B cell assays Supplementary table 4. Phenotyp…
View article: Supplementary Figure 6 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 6 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 6. Splenocytes from complete responders (CR) from ADC-1013 treatment of MB40 tumors were transplanted to naive mice. The receiving naïve mice were then challenged with MB49 tumors and the tumor volume followed over tim…
View article: Supplementary Figure 6 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 6 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 6. Splenocytes from complete responders (CR) from ADC-1013 treatment of MB40 tumors were transplanted to naive mice. The receiving naïve mice were then challenged with MB49 tumors and the tumor volume followed over tim…
View article: Supplementary Figure 2 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 2 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 2. Microphotographs from cryo sections showing representative images of A) Spleen, B) Liver and C) Brain (one slide representing data from one female and one male mice) from hCD40+ mice stained with an anti-human CD40 …
View article: Supplementary Figure 3 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 3 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 3. Anti-tumor effect on MB49 tumors. ADC-1013 generates a significant anti-tumor effect on CD40 negative MB49 cells in hCD40tg mice. Treatment with ADC-1013 or isotype control was performed on day 7 and 10 post tumor i…
View article: Supplementary Figure 2 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Figure 2 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Figure 2. Microphotographs from cryo sections showing representative images of A) Spleen, B) Liver and C) Brain (one slide representing data from one female and one male mice) from hCD40+ mice stained with an anti-human CD40 …
View article: Supplementary Tables from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Supplementary Tables from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Open
Supplementary Table 1. Selection strategy Supplementary Table 2. Kinetic parameters for ADC-1013 and B44 measured by Biacore Supplementary Table 3. In vitro potency (EC50) of ADC-1013 in DC and B cell assays Supplementary table 4. Phenotyp…